AbolerIS Pharma Strengthens Management Team to Support Next Phases of Growth.

Read the press release from February 24th, 2021   

Our Approach 

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

schema aboleris -

Our Company

Founded in November 2019 by Dr. Carole Guillonneau (Director of Research CNRS) and Dr. Ignacio Anegon (Director of Research INSERM), researchers in Center of Research in Transplantation and Immunology (CRTI) UMR1064 INSERM/University of Nantes located at the Nantes University Hospital, together with Dr. François-Xavier Hubert (MD, PhD). AbolerIS Pharma is developing two innovative strategies to finely regulate the immune system: an anti-CD45RC monoclonal antibody and the cytokine IL-34.
 
AbolerIS Pharma received a pre-seed maturation funding from SATT Ouest-Valorisation and was incubated by Atlanpole Biotherapies, the regional competitiveness cluster.
 
In November 2020, Company raised a 2,5M$ in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé.

Our Vision 

Founders

Management

Board of Directors

Scientific Advisory Board